Could a single treatment free kidney patients from daily pills?
NCT ID NCT04803006
First seen Feb 06, 2026 · Last updated May 10, 2026 · Updated 12 times
Summary
This study tested a combination of an experimental drug (siplizumab), donor bone marrow cells, and mild chemotherapy in 4 kidney transplant recipients. The goal was to see if this approach could train the body to accept the new kidney without needing lifelong anti-rejection medication. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.